Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04555642

Enrollment

120

Registered

2020-09-21

Start date

2020-09-15

Completion date

2022-02-28

Last updated

2021-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Magnetic Resonance Imaging, Positron-Emission Tomography

Keywords

Positron-Emission Tomography, cardiotoxicity, Magnetic Resonance Imaging, FDG, FAPI

Brief summary

Using Multi-tracer to early diagnosis of therapy-associated cardiotoxicity using multimodality PET/MRI.

Detailed description

In this study investigators evaluated cardiac uptake by different molecular probe such as FDG, FAPI-04 using multimodality PET/MRI. Previous studies have shown that increased cardiac uptake of FDG on PET may be an indicator of myocardial injury after chemotherapy. Cardiac magnetic resonance (CMR) allows for multiparametric evaluation of cardiac morphology, ventricular function, myocardial perfusion, and viability. The combination of PET with MR (PET/MR) is therefore an alternative attractive pairing for diagnostic imaging. The aim of this study is to find noninvasive and effective method for early diagnosis of cardiotoxicity after chemotherapy or immunotherapy

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* availability of a clinical pre- and post-therapy clinical evaluation encompassing electrocardiogram (ECG) ; * normal findings at pre-therapy clinical evaluation; * cancer planned chemotherapy or immunotherapy scheme ; * available staging FDG-PET/CT scan (PET0);

Exclusion criteria

* cannot lie supine for half an hour; * refuse to join the clinical researcher; * without metal implants.

Design outcomes

Primary

Measure	Time frame	Description
SUVR	150 days	the ratio of the standardized uptake value(SUVR) of multi-tracer for the heart within each time window to that of the normal tissue such as hepatic blood pool、blood pool and gluteus.

Secondary

Measure	Time frame	Description
Change Of Mapping Value and LVEF From Baseline	150 days	The change of mapping value and left ventricular ejection fraction between the value before treatment and the value after treatment was calculated based on cardiac magnetic resonance

Countries

China

Contacts

Primary ContactXuejuan Wang, MD

xuejuan_wang@hotmail.com86 010 88196363

Outcome results